PHIO vs. ATNM, FGEN, BRNS, LTRN, PDSB, AADI, MDCX, NBRV, SCYX, and TELO
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Aadi Bioscience (AADI), Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs. Its Competitors
Phio Pharmaceuticals (NASDAQ:PHIO) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 502.15%. Actinium Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 186.62%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Actinium Pharmaceuticals.
Phio Pharmaceuticals' return on equity of -88.75% beat Actinium Pharmaceuticals' return on equity.
In the previous week, Phio Pharmaceuticals' average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.
Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Phio Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.
Summary
Phio Pharmaceuticals beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 10/7/2025 by MarketBeat.com Staff
